Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05802797 · ClinicalTrials.gov registry record · Early Phase 1

Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules

A Early Phase 1 study of Healthy Diet, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
Early Phase 1
Development phase
24
Enrollment target
1
Study location

NCT05802797: Active Early Phase 1 study of Healthy Diet, sponsored by Ohio State University Comprehensive Cancer Center.

NCT05802797 is a Early Phase 1 study of Healthy Diet that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 24 participants, below the 36,122-participant average among 7 other Healthy Diet trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05802797, a Early Phase 1 study of Healthy Diet, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This study will compare the algae oil fortified soymilk to a commercial algae oil capsule containing the same base oil with the goal of demonstrating equivalent or greater accumulation of EPA and DHA in blood lipid pools.

Primary Outcome

Percent EPA and DHA of total fatty acids in erythrocyte samples

Conditions Studied

Interventions

  • OTHER Algae Oil Fortified Soymilk
  • DIETARY_SUPPLEMENT Algae Oil Capsule

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-04-03
Est. Completion 2026-07-10
Phase Early Phase 1

What the registry record for NCT05802797 still lists

NCT05802797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 36,122-participant average among 7 other Healthy Diet trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Healthy Diet appearing as the primary indexed condition, and to 2 interventions - of which Algae Oil Fortified Soymilk is the first listed.

NCT05802797 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT05802797 about?

NCT05802797 is a clinical study titled "Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules". This study will compare the algae oil fortified soymilk to a commercial algae oil capsule containing the same base oil with the goal of demonstrating equivalent or greater accumulation of EPA and DHA in blood lipid pools.

What is the current status of trial NCT05802797?

This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2023-04-03. Estimated completion is 2026-07-10.

What conditions does trial NCT05802797 study?

This clinical trial studies the following conditions: Healthy Diet.

What interventions are being tested in trial NCT05802797?

The interventions under investigation include: Algae Oil Fortified Soymilk (OTHER), Algae Oil Capsule (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05802797?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05802797 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Diet

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05802797, the US trial registry maintained by the National Library of Medicine. NCT05802797 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.